Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of FLUAD (2009-2010 Formulation) in Elderly Subjects
NCT00956761Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Primary completion
- Jun 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of influenza vaccine (surface antigen, inactivated, adjuvanted) in seasonal influenza, sponsored by Novartis. Primary endpoints: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area at Day 21, Geometric Mean Ratio of Participants Against Each of the Three Vaccine Strains at Day 21 and 2 more. Started Jun 2009; status: completed.
02
Drugs
influenza vaccine (surface antigen, inactivated, adjuvanted)
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT00956761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00956761.